Skip to main content

Table 1 Mean overall survival and progression-free survival in metastatic breast cancer subdivided on the basis of circulating tumor cell positivity

From: Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study

  OS, months 95% CI, months P value PFS, months 95% CI, months P value
Total 23.174 20.4-25.9 - 10.2 9.1-11.3 -
CellSearch™       
   ≥1 CTC(s) 19.6 17.1-22.2 <0.01 9.8 8.5-11.0 n.s.
   <1 CTC 30.1 26.3-33.9   10.9 8.8-12.9  
   ≥5 CTCs 18.1 15.1-21.1 <0.01 9.3 7.8-10.9  
   <5 CTCs 27.1 23.5-30.7   10.9 9.3-12.5 n.s.
AdnaTest Breast™       
   CTC-positive 19.3 15.4 - 23.1 n.s. 8.8 7.2-10.4 n.s.
   CTC-negative 23.8 20.3-27.5   10.7 9.2-12.2  
  1. CTC, circulating tumor cell; n.s., not significant; OS, overall survival; PFS, progression-free survival.